Thyroid evaluation performed before starting DAAs therapy, showed a high prevalence of thyroid alterations (20/113, 17.7%) in the whole series, being greater (15/49, 30.6%) in IFN-α group (mainly represented by HT), compared to naïve group (5/64, 7.8%); this latter consisted in few cases of non-autoimmune subclinical thyroid dysfunction. This evidence concerns the gene IFNA17 and hematocrit.